Rezolute is trading 7.18% down at $3.62 after several consecutive sessions of declines, with biotech-sector weakness potentially contributing.
- No clear company-specific catalyst was identified for the October 16 move.
- On October 14, Rezolute reported Phase 3 upLIFT enrollment was complete and expected topline results in mid-December; the announcement did not link the decline to the update.
- The provided sector context shows XBI down 2.06%.